Annual report pursuant to Section 13 and 15(d)

Intangible Assets (Details Narrative)

v3.19.3.a.u2
Intangible Assets (Details Narrative) - USD ($)
12 Months Ended
Mar. 19, 2018
Oct. 04, 2017
Dec. 31, 2019
Dec. 31, 2018
Dec. 23, 2019
Number of shares acquired in exchange for common stock     298,615  
Common stock shares issued     5,486,476 5,525,009  
Common stock shares outstanding     5,486,476 5,525,009 38,404,530
Amortization expense     $ 795,328 $ 621,647  
Future amortization expense,thereafter     788,000    
Product Concentration Risk [Member] | Sub License [Member]          
Sales percentage   10.00%      
CoNCERT Pharmaceuticals, Inc [Member]          
Capitalized cost $ 11,038,929        
Recognition of deferred tax liability 3,037,147        
Intangible asset, tax basis $ 1,782        
Number of shares acquired in exchange for common stock 298,615        
Shares acquired price per share $ 26.79        
Common stock shares issued 5,039,033        
Common stock shares outstanding 5,039,033        
Fair value of intangible asset received in exchange for common stock $ 8,000,000        
Sublicense royalty percantage 15.00%        
Sales percentage description We will pay the greater of (i) 6% or (ii) 50% of all payment received by us with respect to such sublicencee. We will also pay 15% of any sublicense revenue earned by us for a period equivalent to the royalty term (as defined in the CoNCERT Agreement) until the earliest of (a) our raising $8 million of gross proceeds and (b) CoNCERT being able to sell its shares of our common stock without restrictions pursuant to the terms of the amended Agreement.        
CoNCERT Pharmaceuticals, Inc [Member] | Catagory 1 [Member] | Maximum [Member]          
Amount of sales limit   $ 100,000,000      
CoNCERT Pharmaceuticals, Inc [Member] | Catagory 1 [Member] | Product Concentration Risk [Member]          
Sales percentage   4.00%      
CoNCERT Pharmaceuticals, Inc [Member] | Catagory 2 [Member] | Maximum [Member]          
Amount of sales limit   $ 500,000,000      
CoNCERT Pharmaceuticals, Inc [Member] | Catagory 2 [Member] | Minimum [Member]          
Amount of sales limit   $ 100,000,000      
CoNCERT Pharmaceuticals, Inc [Member] | Catagory 2 [Member] | Product Concentration Risk [Member]          
Sales percentage   5.00%      
CoNCERT Pharmaceuticals, Inc [Member] | Catagory 3 [Member] | Maximum [Member]          
Amount of sales limit   $ 1,000,000,000      
CoNCERT Pharmaceuticals, Inc [Member] | Catagory 3 [Member] | Minimum [Member]          
Amount of sales limit   $ 500,000,000      
CoNCERT Pharmaceuticals, Inc [Member] | Catagory 3 [Member] | Product Concentration Risk [Member]          
Sales percentage   6.00%      
CoNCERT Pharmaceuticals, Inc [Member] | Catagory 4 [Member] | Minimum [Member]          
Amount of sales limit   $ 1,000,000,000      
CoNCERT Pharmaceuticals, Inc [Member] | Catagory 4 [Member] | Product Concentration Risk [Member]          
Sales percentage   10.00%      
Software License [Member] | CoNCERT Pharmaceuticals, Inc [Member]          
Capitalized cost     $ 20,500